Strata oncology trial#
Strata oncology series#

If a physician orders the StrataNGS® test for comprehensive molecular profiling, no additional tissue is required to perform StrataEXP. We currently provide StrataEXP results as supplemental information in order to offer physicians broader molecular insights into each patient’s cancer. StrataEXP uses RNA-sequencing to generate quantitative expression results from 10 expression biomarkers, which are targeted by multiple approved and investigational therapies, including antibodies, antibody drug conjugates, radiopharmaceuticals and immunotherapies. Strata Oncology to Help Identify Patients for NCI-MATCH Precision Medicine Study. is a precision medicine company dedicated to transforming cancer care by building a platform to systematize precision oncology across a network of health systems and biopharma companies.

The 46 gene panel used for the assay was developed from data generated in conjunction with the StrataNGS test. Strata Oncology has a post-money valuation in the range of 100M to 500M as of Jul 28. Wellington Management and Baird Capital are the most recent investors. Strata Oncology is funded by 12 investors.

Strata oncology series#

Their latest funding was raised on from a Series C round. StrataEXP is a laboratory-developed multi-gene expression test. Strata Oncology has raised a total of 128M in funding over 3 rounds. Single-/multi-nucleotide variants (SNVs), short insertions and deletions (indels), copy number alterations (CNAs amplifications and deep deletions), microsatellite instability (MSI) status, gene fusions, and tumor mutation burden (TMB) are assessed simultaneously. The 429-gene assay is performed on co-isolated RNA and DNA. StrataNGS is a comprehensive genomic profiling (CGP) test that features the lowest tumor tissue requirements in the industry (>2mm2 surface area). Our ability to provide deep cancer insights from minute tumor tissue samples ensures that more of your patients have the opportunity to benefit from precision medicine. The Strata Oncology tumor profiling platform combines DNA and RNA sequencing to deliver comprehensive cancer insights to help providers manage patients with advanced cancer. Strata Oncology to Present at 40th Annual J.P.Comprehensive treatment insights for more patients using less tissue. Strata Oncology Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022 March 8, 2022

Strata oncology trial#

Strata Oncology Sentinel Trial for Personalized Cancer Recurrence Monitoring Enrolls First Patient March 16, 2022 Strata Oncology Appoints Sundu Brahmasandra as Chief Operating Officer March 22, 2022 Strata Oncology Receives Honorable Mention in the Health Category of Fast Company’s 2022 World Changing Ideas Awards May 3, 2022 Strata Oncology Enrolls First Patient in Strata PATH Trial Investigating New Pan-Tumor Indications for Approved Cancer Therapies May 11, 2022 Strata Oncology Expands Strata PATH Trial with Two New Partners May 25, 2022 Strata Oncology Senior Vice President of Clinical Development Kat Kwiatkowski to Participate in Two Panels at Precision Medicine World Conference June 16, 2022

Strata Oncology Expands Sentinel Trial with Lehigh Valley Topper Cancer Institute and University of Michigan Health Rogel Cancer Center to Bring Precision Therapies to Patients Earlier in Their Cancer Journey June 23, 2023 Strata Oncology Expands Strata PATH Trial to Eight Sarah Cannon Research Institute Sites August 16, 2022